Evaluation of the Osteosarcoma Chemotherapy Regimens and its Treatment Results in Meshed Omid Hospital

This study was designed to evaluate results of neoadjuvant and adjuvant chemotherapy for nonmetastatic osteosarcoma patients. Forty four patients who were referred to Omid hospital from 1994 to 1999 were eligible to the study. For comparison based on different chemotherapy regimens which had been prescribed, all patients were classified into 3 different subgroups named as HDMTX (including high dose methotrexate and other drugs based on a protocol known as T10), 3 drugs (low dose methotrexate, vincristine and cyclophosphamide) and 4 drugs (low to intermediate dose methotrexate, vincristine, cyclophosphamide and adriamycine) regimens. While 2 and 5 years Relapse Free Survival (RFS) were 45% and 28% respectively, there was not any significant statistical difference between the groups. In addition Median Event Free Survival (MEFS) was 18.5 months and again there was not any significant statistical difference between groups (15.5 months for HDMTX, 21 months for 3 drugs and 24 months for 4 drugs regimens). Considering as a prognostic factor, effects of adriamycin prescription, neoadjuvant chemotherapy and adequacy of chemotherapy courses in MEFS were evaluated. Putting Adriamycin into regimen and adequacy of chemotherapy courses had a significant effect on MEFS improvement but neoajuvant chemotherapy didn’t have such a significant effect. As methotrexate was integrated into all different regimen however with different doses the study didn’t show improving MEFS with increasing doses of this drug.